News

RECAP: COVend at Euroanaesthesia 2025 – ARDS in Europe: data and clinical trials

We are proud to report a successful presence of COVend at Euroanaesthesia 2025, held in Lisbon from 25–27 May. Organised by our project partners at ESAIC, the event is one of Europe’s leading congresses for anaesthesia and intensive care professionals. This year’s edition brought together thousands of experts from across Europe and beyond to explore the latest in critical care innovation, COVend included.

Read More »

COVend Webinar | From COVID-19 to ARDS: Adapting Our Clinical Trial to Real-World Conditions

The Horizon Europe-funded COVend project invites you to a one-hour online webinar exploring how a pandemic-driven clinical trial has evolved to address Acute Respiratory Distress Syndrome (ARDS) using a mechanism-based approach. As the IXION 2.0 clinical trial transitions from a COVID-19 focus to a broader ARDS treatment strategy, COVend experts will discuss the scientific rationale behind this shift, as well as the clinical and operational challenges encountered along the way.

Read More »

Interview with Zhiran Wang: Unravelling the Science Behind COVend

The COVend project is dedicated to developing innovative treatments for COVID-19 and its complications. One of the researchers at the heart of this effort is Zhiran Wang, a PhD student at University College Dublin, whose work focuses on understanding vascular damage in COVID-19 patients and the potential of the FX06 drug candidate.

Read More »

Major Milestone Reached: COVend’s IXION 2.0 trial enrols its first patients!

We are excited to announce the start of patient enrollment for the IXION 2.0 clinical trial at the Goethe University Hospital Frankfurt. Due to the evolving dynamics of COVID-19, the project’s focus has shifted to investigating the potential benefits of the FX06 drug for patients with acute respiratory distress syndrome (ARDS). Spearheaded by Prof. Zacharowski and Dr. Petra Wülfroth, the co-founder of F4 Pharma in Vienna, the consortium and clinical trial were restructured in record time, underlining the unwavering joint commitment to innovative medical research in critical health conditions.

Read More »

Groundbreaking research on Idiopathic Systemic Capillary Leak Syndrome: FX06 is Pioneering New Frontiers in Clarkson Disease Treatment

Our COVend consortium member F4 Pharma’s cooperation partners presented groundbreaking research on Idiopathic Systemic Capillary Leak Syndrome (ISCLS), also known as Clarkson disease, first at the 124° Congresso Nazionale of the Societa Italiana di Medicina Interna (SIMI) in October 2023. Now their paper is officially published in Biomedicine & Pharmacotherapy.

Read More »

COVend presented at ISPOR Europe 2023

On the 13th of November, the consortium member of our partner institution UMCG, Clazinus Veijer, presented his poster “Lessons learned from model-based economic evaluations of COVID-19 treatments under pandemic circumstances: results from a systematic review ” at ISPOR Europe 2023. The poster highlighted results from a systematic review of various methodological characteristics of model-based economic evaluations of COVID-19 treatments.

Read More »
image depicting two SDG icons

COVend and UN SDGs: Contributing to Shaping a Healthier World

In 2015, the United Nations adopted the 17 Sustainable Development Goals (SDGs) as a global blueprint for addressing pressing challenges. These goals guide our efforts to combat poverty, inequality, climate change, and environmental concerns. Among them, two pivotal goals stand out – SDG 3: Good Health and Well-being, and SDG 9: Industry, Innovation and Infrastructure.

Read More »
image depicting a loudspeaker and the announcement "Big news for the COVend project"

New Findings on FX06 and its Therapeutic Potential from the COVend Research Teams

What do an economist, a biochemist, and a clinician have in common? As it turns out, they can all benefit from the latest findings on FX06. The researchers from University College Dublin and the University Medical Center Groningen, the esteemed COVend consortium partners, have revealed new information on FX06 and its potential role in addressing hyperinflammation and capillary leak.

Read More »